Sun, Feb 1, 2015, 12:41 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Dec 12, 2012 7:42 PM Flag


    Morgan Stanley
    December 5, 2012
    Onyx Pharmaceuticals
    PD-991, A Nice to Have
    Impact on our views: Phase II data for Pfizer’s (covered by David Risinger) CDK 4/6 inhibitor PD 0332991 (PD-991) in metastatic breast cancer (mBC) look good. Onyx is entitled to a single-digit royalty creating a new (albeit limited) revenue driver for the stock in 2016+.

    Strong showing on PFS. Median PFS was 26.1 months for patients on the PD-991 + letrozole (LET) arm vs 7.5 months for letrozole (Exhibit 1) with a hazard ratio of 0.37 (95% CI 0.21, 0.63), an impressive result. As is typical with Phase II oncology trials, a handful of patients drive the PFS curves at the longer time points so the robustness of the 18.6-month PFS benefit remains a question (23 vs 41 progression events for PD-991 and control, respectively).

    PD-991 valuation suggests ~$1-3 per share (Exhibit 2). Onyx receives an undisclosed single digit royalty on PD-991. Our sensitivity analysis of peak PD-991 sales ($0.5B - $2B) and royalty (3-5%) suggests an NPV per share of $1-3 assuming: 1) launch late 2016/early 2017, 2) a patent life with extensions to 2035 (MSe), and 3) a 50% risk-adjustment on eventual commercialization. However, the revenue opportunity is unclear as median treatment duration was just 8.9 months.

    Sentiment: Strong Buy

124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.